These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37633424)

  • 1. Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel.
    Senneville E; Cuervo G; Gregoire M; Hidalgo-Tenorio C; Jehl F; Miro JM; Seaton A; Söderquist B; Soriano A; Thalhammer F; Pea F
    Int J Antimicrob Agents; 2023 Nov; 62(5):106960. PubMed ID: 37633424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Ramdeen S; Boucher HW
    Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
    Roecker AM; Pope SD
    Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
    Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
    Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Garnock-Jones KP
    Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of plasma protein binding of dalbavancin.
    Turner NA; Xu A; Zaharoff S; Holland TL; Lodise TP
    J Antimicrob Chemother; 2022 Jun; 77(7):1899-1902. PubMed ID: 35488862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.
    Cacopardo B; Cattaneo D; Cortese F; Di Luca M; Falcone M; Marchetti G; Tascini C; Tiseo G; Venditti M
    Expert Rev Anti Infect Ther; 2022 Jul; 20(7):997-1004. PubMed ID: 35353020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
    Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
    Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.
    Dash RP; Babu RJ; Srinivas NR
    Infect Dis (Lond); 2017 Jul; 49(7):483-492. PubMed ID: 28264598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.